| INTRODUCTION
Gastric cancer (GC) remains the third most frequent cause of cancer-related deaths. It ranks the fifth in cancer incidence in the world. 1 Similar to that in Japan and China, GC in Korea has the second most-frequent incidence (61.3/100 000). It is the third leading cause of cancer-related deaths (18.6/100 000) in Korea. 2 Primary prevention by risk factor modification and early detection for GC is important. [3] [4] [5] To reduce its socioeconomic burden, strategies are needed. 6 Risk factors of GC include Helicobacter pylori (H. pylori) infection, salt intake, smoking habit, alcohol consumption, male sex, low socioeconomic status, family history for GC, and existence of atrophic gastritis (AG) and intestinal metaplasia (IM). [7] [8] [9] [10] [11] [12] [13] [14] [15] H. pylori eradication reduces the incidence risk of GC in H. pylori infected patients. [16] [17] [18] Many studies have evaluated the mechanism of GC prevention by H.
pylori eradication. [19] [20] [21] However, such mechanism has not been clarified. Although AG and IM are risk factors for GC, they have not been included in absolute indication of H. pylori eradication. [22] [23] [24] Furthermore, H. pylori eradication is not strongly recommended or covered by medical insurance for GC prevention, especially when the severity of AG and IM is high because of their uncertain reversibility.
In H. pylori infection, the gastric mucosa progresses through multiple stages of chronic gastritis, AG, and IM. These are risk factors for GC. 8, 11, 25, 26 Theoretically, regression of AG and IM is important to prevent intestinal-type GC. 27 As H. pylori infection is the most important cause of AG and IM 25, 28 H. pylori eradication would diminish the development of intestinal-type GC by regression of AG and IM. However, conflicting results have been presented concerning whether AG and IM are improved by H. pylori eradication. [29] [30] [31] [32] [33] In some reports, H. pylori eradication improved AG and IM. 32, [34] [35] [36] [37] [38] However, such result is not found in other studies. 33, [39] [40] [41] Wong et al have suggested a "point of no return" in terms of the effect of H. pylori eradication for GC prevention. 30 Kiriyama et al have also stated that mucosal damage of IM stage cannot improve to normal gastric mucosa due to "histological point of no return." 39 However, these studies had limitations in study design, including small cohorts or insufficient follow-up periods with histological diagnosis. 6, 40 With this background, we hypothesised that the reversibility of AG and IM after H. pylori eradication might occur sequentially and take a long time, especially in case of IM. Therefore, the objective of this study was to evaluate the reversibility of AG and IM by serial comparison between baseline and follow-up grades of AG and IM in a large Korean cohort with a long follow-up. In Korea, over 50% of the population are infected with H. pylori, 28 In addition, follow-up grades of AG and IM in H.
pylori-eradicated group were compared with those of H. pylorinegative and H. pylori non-eradicated groups. The time line until the disappearance of AG and IM during the long-term follow-up was also analysed. and July 31, 2015 were prospectively enrolled ( Figure 1 ). They completed a questionnaire under the supervision of a well-trained interviewer. 4 The questionnaire solicited information about family history for GC, intake of salty and spicy food during the past 6 months, alcohol consumption, smoking, and socioeconomic status (including education and monthly income). In terms of alcohol consumption, subjects were classified as current drinkers (those who drank alcohol once a week or more), ex-drinkers (those who had quit drinking), and nondrinkers (those who had never drank). Salty and spicy food intake was classified as low/middle and high intake according to subject's answer about the habit of adding salt or spice (red pepper, garlic, and ginger) with their meals. It is known that the incidence of GC is significantly higher in people ≥65 years in Korea (15-34 years:
2.4/100 000, 35-64 years: 95.3/100 000 and ≥ 65 years: 412.5/ 100 000). 2 Therefore subjects were categorised into two age groups (< 65 years or ≥ 65 years).
Subjects received esophagogastroduodenoscopy (EGD) to check the presence of GC or precancerous lesions such as dysplasia. 7 Subjects with pathologically proven gastric dysplasia or GC (n = 350)
were excluded ( Figure 1 ). Subjects with previous gastrointestinal surgery or severe medical diseases such as liver cirrhosis, chronic renal failure, brain diseases, or cardiovascular diseases were also excluded.
This study protocol was approved by the Institutional Review
Board of SNUBH (B-0602/030-001). Written informed consent was obtained from all subjects following ethical principles for medical research of the 53th World Medical Association Declaration of Helsinki. 42 This study protocol has been registered at ClinicalTrials.gov (NCT02691637). All authors had access to study data and approved the final manuscript.
| Esophagogastroduodenoscopy, Helicobacter pylori tests, and histology
Esophagogastroduodenoscopy (EGD) and biopsy were performed by a single doctor (Nayoung Kim) for consistency in biopsy sites. At initial EGD, 10 biopsy specimens were obtained for Helicobacter pylori (H. pylori) examinations such as modified Giemsa stain, cultures and rapid urease test (CLOtest), and histological examination for atrophic gastritis (AG) and intestinal metaplasia (IM). Biopsy sites were distributed evenly in the mid antrum and mid corpus. From these sites, six specimens from the lesser curvature for modified Giemsa stain, culture and CLOtest, and four specimens from the greater curvature for modified Giemsa stain and culture were evenly obtained from the mid antrum and the mid corpus ( Figure S1a ). 4, [43] [44] [45] Each subject HWANG ET AL. 
| Definition of atrophic gastritis and intestinal metaplasia improvement

Improvement of atrophic gastritis (AG) and intestinal metaplasia (IM)
was defined when consistent decrease in AG and IM was observed over the follow-up period with at least one grade difference based on the Undated Sydney Classification System. Each subject initially diagnosed as AG and IM (grade >0) was analysed for each antrum and body. We carefully applied this definition because histological diagnosis was based on focal biopsy specimens while AG and IM showed patchy distribution when it was not severe. | 383
Characteristics of these 548 subjects finally included in the analysis are shown in group, grades of AG in both antrum and corpus decreased significantly at all follow-up timepoints compared to those at baseline (both P < 0.001 for all timepoints) (Figure 2a) . After ≥1 year post eradication, grades of AG in the antrum and corpus improved from those at 1-year follow-up. However, there were not significantly different from those in the H. pylori-negative group for antrum and corpus after 1, 2, 3-4, and ≥5 years (antrum: P = .08, P = .08, P = .03 and P = .17, respectively; corpus: P = .11, P = .06, P = .18 and P = 1.00 respectively) (Figure 2a) . In H. pylori-negative or H. pylori noneradicated group, there were no significant changes in grades of AG in both of the antrum and the corpus after 1, 2, 3-4, and ≥ 5 years in comparison to grades at baseline (Figure 2a ).
Response of IM to H. pylori eradication was slightly different from that of AG. In the eradicated group, grades of IM in both antrum and corpus continuously decreased from the 1-year followup compared to those at baseline (both P < .001 for all time periods) (Figure 2b ). However, IM in antrum and corpus did not reach the degree of the H. pylori-negative group at 2 years after eradication (both P < .05). At ≥5 years after eradication, grades of IM in the antrum improved to levels that were not significant different compared to those of the H. pylori-negative group for the antrum (P = .208; Figure 2b ). At ≥3 years after eradication, grades of IM in the corpus improved to levels that showed no significant difference compared to those of the H. pylori-negative group for the corpus (P = .08 and P = .20, respectively; Figure 2b) . In H. pylori-negative or H. pylori non-eradicated group, there was no significant change in grades of IM in either the antrum or the corpus after 1, 2, 3-4 or ≥5 years compared to those at baseline (Figure 2b ).
| Improvement of atrophic gastritis and intestinal metaplasia by analysing each subject and comparison between Helicobacter pylori-eradicated and Helicobacter pylori non-eradicated groups
Improvement of each subject's atrophic gastritis (AG) and intestinal metaplasia (IM) was carefully analysed with strict criteria ( Figures S2, S3,   S4 ). Improvement of each subject's AG and IM was compared between
Helicobacter pylori (H. pylori)-eradicated and H. pylori non-eradicated groups (Table 2, Figure 2 ). In the antrum, AG and IM in the H. pylori-eradicated group were significantly improved in comparison with those of the H. pylori non-eradicated group (P = .03 and P < .001 respectively). AG and IM in the H. pylori-eradicated group were also significantly improved compared to those of the H. pylori non-eradicated group in the corpus (P < .001 and P < .01, respectively; Table 2, Figure 2 ).
To investigate when such histological improvement was achieved, each subject's improvement of AG and IM up to grade 0 was analysed (Table 3) (P = .002 and P = .01 respectively) ( Table 3) . We classified one group of AG and IM improvement up to grade 0 in H. pylori-eradicated group and drew cumulative rate graphs for date in Table 3 ( Figure 3 ). These graphs also showed that AG was regressive more quickly than IM. IM regressed to grade 0 after a long term follow-up after H. pylori eradication. This result was difficult from those of other studies with shorter follow-up than our study. In the H. pylori-eradicated group, grades of atrophic gastritis in both antrum and corpus significantly decreased at all follow-up timepoints compared to those at baseline (both P < .001 for all perioids) (A). The difference in atrophic gastritis grade between the H. pylori-eradicated group and H. pylori-negative disappeared from 1 year after eradication. In contrast, atrophic gastritis grades after 1, 2, 3-4 and ≥5 years in H. pylori-negative and H. pylori non-eradicated groups did not show significant change compared to those at baseline (A). Similarly, grades of intestinal metaplasia continuously decreased in both antrum and corpus compared to those at baseline from the 1-year follow-up (both P < .001 for all periods) (B). However, intestinal metaplasia in the H. pylori-eradicated group showed no statistical difference in comparison with that in the H. pylori-negative group at ≥5 years post-eradication in the antrum and after ≥3 years in the corpus (B). In contrast, grades of intestinal metaplasia in either the antrum or the corpus after 1, 2, 3-4 and ≥5 years showed no significant change compared with those at baseline in the H. pylori-negative or the H. pylori non-eradicated group (B) only a few articles have addressed the reversibility of IM. 58 Others have reported that IM does not improve after H. pylori eradication. 30, 34, 35, 41, 59 To clarify this controversy, large cohort-based and long-term follow-up studies are necessary. 60 Studies also need to use strict standards for improvement of AG and IM as shown in this study. In our study, AG and IM in both the antrum and the corpus continuously improved after H. pylori eradication until reaching a point that they were not significant different compared to those in the H. pylori-negative group. This finding is different from a prior meta-analysis showing that the improvement of AG only occurs in the corpus, not in the antrum. 61 However, follow-up range of 12 studies included in their meta-analysis was 1-6.7 years with only four studies having ≥5 years of follow-up. 61 In contrast, this study featured a large cohort with a longitudinal follow-up for AG and IM.
Furthermore, grades of IM in the antrum and corpus decreased from 1-year post eradication in this study, different from several previous studies. [58] [59] [60] [61] [62] The speed or degree of reversibility was found to be different between AG and IM. Grades of IM did not improve after ≥ 28 It has been reported that the appearance of gastric IM is associated with aberrant expression of CDX1 and CDX2, 69, 70 suggesting that the improvement of IM might require down-regulation of CDX1 and CDX2. 71 Both CDX1 and CDX2 mRNA levels are decreased with improvement of IM but increased with the aggravation of IM. 69 Our study has some limitations. First, it is not a randomised controlled study. Initially, a randomised controlled trial was planned.
Before enrolment, we explained our study purpose to possible participants regarding AG and IM and that H. pylori could be the most important cause of AG and IM. When they realised that eradication of H. pylori eradication was important for prevention of GC as well as for resolving AG and IM, they refused to participate in a randomised controlled study. Instead they wanted to receive H. pylori eradication therapy, especially when they were the first degree relative of GC patients. This is similar to a previous report. 72 Finally we changed our study design from randomised control study to a case-control study following the advice of the Institutional Review
Board at Seoul National University Bundang Hospital IRB. Thus H.
pylori-eradicated subjects were outnumbered by H. pylori non-eradicated subjects. To reduce confounding effects of a case-control study, pathologic and statistic researchers were blinded to the sub- subjects (mean age 57.6 years; 1506 men and 1052 women). In one study, inadequate (not applicable) atrophic gastritis rate for the assessment was 27.8% in the antrum and 21.8% in the corpus due to several problems such as inadequate orientation at the stage of fixation or dense inflammation. 73 To avoid such limitation, only one pathologist (H.S.L) observed biopsy specimen to diagnose and grade AG and IM. In spite of these limitations, our study enrolled a relatively large number of subjects with a long-term follow-up compared to other studies. 6, 40 In addition; we restrictedly defined H. pylori status, biopsy protocols and improvement of AG and IM to improve accuracy and reliability of our study. Our study's message is very clear. That is, AG and IM are reversible and H. pylori eradication is valuable for GC prevention. H. pylori eradication as a prevention strategy for intestinal-type GC by regression of AG and IM has been implemented in Japan. 74 So far, a "point of no return" has suggested that H. pylori eradication is effective only before AG and IM reaches certain point for GC prevention. 30 We have previously reported that H. pylori eradication and B allele can decrease the risk of intestinal-and diffuse-types of non-cardiac GC. 4 Results of this study suggest that H. pylori eradication regresses AG and IM, thus providing a mechanism to prevent intestinal-type GC by H. pylori eradication.
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